NCT07622212 Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis
| NCT ID | NCT07622212 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Deep Vein Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2024-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A head-to-head comparison of two different types of percutaneous mechanical thrombectomy (PMT) - ClotTriever System versus aspiration thrombectomy (including rheolytic thrombectomy) - in patients with acute iliofemoral deep vein thrombosis (DVT) was conducted to determine whether ClotTriever System can improve thrombus clearance rate, reduce the incidence of post-thrombotic syndrome (PTS), and enhance the long-term efficacy of endovascular treatment for acute iliofemoral DVT.
Eligibility Criteria
Inclusion Criteria: 1. Aged between 18 and 85 years; 2. Diagnosed with acute iliofemoral venous thrombosis, with thrombosis involving at least the iliac vein and common femoral vein; 3. Time from symptom onset to endovascular treatment ≤ 14 days; 4. Patients undergo endovascular treatment with percutaneous mechanical thrombectomy; 5. Patients sign the informed consent form. Exclusion Criteria: 1. Presence of PTS in the limb to be treated in this procedure, or a history of symptomatic DVT in the same limb within the past 2 years; 2. Concurrent symptomatic acute DVT involving the iliac vein and/or common femoral vein in the contralateral limb; 3. Known allergy to heparin, low molecular weight heparin, contrast agents, etc. 4. Concomitant severe pulmonary embolism with hemodynamic changes, such as hypoxia, hypotension, etc. 5. Inability to tolerate endovascular treatment due to conditions such as acute systemic illness, severe dyspnea, etc. 6. Concomitant severe renal insufficiency with creatinine clearance \< 30 ml/min; 7. Concomitant active bleeding, severe hepatic insufficiency, bleeding tendency, etc. 8. Concomitant severe anemia (hemoglobin \< 8.0 mg/dL) or platelet count \< 80,000/mL; 9. History of subarachnoid hemorrhage, intracranial hemorrhage, intracranial vascular malformation, or intracranial aneurysm; 10. Pregnant women; 11. Presence of other diseases (e.g., advanced malignancy, cardiac insufficiency, etc.) with an expected life expectancy \< 24 months 12. Participation in any drug or medical device clinical trial that may interfere with this study within the past 1 month; 13. Patients unwilling to participate in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07622212 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Deep Vein Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07622212 currently recruiting?
Yes, NCT07622212 is actively recruiting participants. Contact the research team at niqihong1989@163.com for enrollment information.
Where is the NCT07622212 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07622212 clinical trial?
NCT07622212 is sponsored by RenJi Hospital. The trial plans to enroll 180 participants.